<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086045</url>
  </required_header>
  <id_info>
    <org_study_id>ELX-CL-1003</org_study_id>
    <nct_id>NCT02086045</nct_id>
  </id_info>
  <brief_title>Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial</brief_title>
  <official_title>A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixir Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elixir Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, performance and efficacy of the Elixir DESolve® Novolimus Eluting&#xD;
      Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native&#xD;
      coronary artery lesion designated the target lesion and up to one non-target lesion located&#xD;
      in a separate epicardial vessel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically-indicated major adverse cardiac events (MACE)</measure>
    <time_frame>6 months</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 month</time_frame>
    <description>MLD post procedure - MLD at follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>1 month</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>12 months</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>24 months</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>3 years</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>4 years</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>5 months</time_frame>
    <description>cardiac death, target vessel MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>1 month</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>6 months</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>4 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Lesion Failure (TLF)</measure>
    <time_frame>5 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Vessel Failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>cardiac death, MI, clinically indicated TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Vessel Failure (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Vessel Failure (TVF)</measure>
    <time_frame>3 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Vessel Failure (TVF)</measure>
    <time_frame>4 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Target Vessel Failure (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>cardiac death, MI, clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold Thrombosis</measure>
    <time_frame>through 5 years</time_frame>
    <description>ARC defined</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute success - Procedure success</measure>
    <time_frame>7 days</time_frame>
    <description>Acute Success is classified according to the following definitions:&#xD;
Procedure success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of &lt; 50% by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of ischemia driven major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days post index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute success - Device success</measure>
    <time_frame>7 days</time_frame>
    <description>Acute Success is classified according to the following definitions:&#xD;
Device success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis &lt; 50% by QCA (by visual estimation if QCA is unavailable). Standard pre-dilation catheters and post-dilatation catheters (if applicable) may be used. Bailout subjects will be included as device success only if the above criteria for clinical device success are met.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DESolve Novolimus Eluting Bioresorbable Coronary Scaffold</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>DESolve Scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System</intervention_name>
    <description>percutaneous coronary</description>
    <arm_group_label>DESolve Novolimus Eluting Bioresorbable Coronary Scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be at least 18 years of age and for the 35-patient subset, patients must&#xD;
             be over the age of 50&#xD;
&#xD;
          -  Patient is able to verbally confirm understanding of risks, benefits and treatment&#xD;
             alternatives of receiving the DESolve Nx Novolimus Eluting BCSS and he/she provides&#xD;
             written informed consent, as approved by the appropriate Ethics Committee of the&#xD;
             respective clinical site, prior to any clinical study related procedure&#xD;
&#xD;
          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,&#xD;
             silent ischemia, positive functional study or electrocardiogram (ECG) changes&#xD;
             consistent with ischemia)&#xD;
&#xD;
          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery&#xD;
&#xD;
          -  Patient must agree to undergo all clinical study required follow-up visits,&#xD;
             angiograms, and as applicable, IVUS, OCT, MSCT and coronary vasomotion testing&#xD;
&#xD;
          -  Patient must agree not to participate in any other clinical study for a period of two&#xD;
             years following the index procedure&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
        Target lesion must be located in a native coronary artery with a nominal vessel diameter of&#xD;
        between 2.75 and 3.5 mm assessed by online QCA&#xD;
&#xD;
          -  Target lesion must measure ≤ 14 mm in length&#xD;
&#xD;
          -  Target lesion must be in a major artery or branch with a visually estimated stenosis&#xD;
             of ≥ 50% and &lt; 90% with a TIMI flow of ≥ 1&#xD;
&#xD;
          -  Percutaneous intervention of lesions in the target vessel if:&#xD;
&#xD;
               1. Not part of a clinical investigation&#xD;
&#xD;
               2. ≥ 6 months prior to the study index procedure&#xD;
&#xD;
               3. ≥ 9 months after the study index procedure (planned)&#xD;
&#xD;
               4. Previous intervention was distal to and &gt;10mm from the target lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours&#xD;
             preceding the index procedure and CK and CK-MB have not returned within normal limits&#xD;
             at the time of procedure&#xD;
&#xD;
          -  Patient is currently experiencing clinical symptoms consistent with AMI&#xD;
&#xD;
          -  Patient requires the use of any rotablator intervention during the index procedure&#xD;
&#xD;
          -  Patient has current unstable arrhythmias&#xD;
&#xD;
          -  Patient has a known left ventricular ejection fraction (LVEF) &lt; 30%&#xD;
&#xD;
          -  Patient has received a heart transplant or any other organ transplant or is on a&#xD;
             waiting list for any organ transplant&#xD;
&#xD;
          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30&#xD;
             days prior to or after the procedure&#xD;
&#xD;
          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or&#xD;
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus&#xD;
             etc.)&#xD;
&#xD;
          -  Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that&#xD;
             cannot be stopped and restarted according to local hospital standard procedures.&#xD;
&#xD;
          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and&#xD;
             bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast&#xD;
             sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
          -  Elective surgery is planned within the first 6 months after the procedure that will&#xD;
             require discontinuing either aspirin or clopidogrel&#xD;
&#xD;
          -  Patient has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;&#xD;
             3,000 cells/mm3, or documented or suspected liver disease.&#xD;
&#xD;
          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5&#xD;
             mg/dL, or patient on dialysis)&#xD;
&#xD;
          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological&#xD;
             attack (TIA) within the past six months&#xD;
&#xD;
          -  Patient has had a significant GI or urinary bleed within the past six months&#xD;
&#xD;
          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion&#xD;
&#xD;
          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known&#xD;
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause&#xD;
             non-compliance with the clinical study plan, confound the data interpretation or is&#xD;
             associated with a limited life expectancy (i.e., less than one year)&#xD;
&#xD;
          -  Patient is already participating in another clinical study&#xD;
&#xD;
          -  Women of childbearing potential who have not undergone surgical sterilization or are&#xD;
             not post-menopausal (defined as amenorrheic for at least one year) as well as women&#xD;
             who are pregnant or nursing&#xD;
&#xD;
          -  Patient is unable to give their consent, is legally incompetent, or is&#xD;
             institutionalized by virtue of an order issued by the courts or other authority&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          -  Target lesion(s) meets any of the following criteria:&#xD;
&#xD;
               1. Aorto-ostial location&#xD;
&#xD;
               2. Left main location&#xD;
&#xD;
               3. Located within 5 mm of the origin of the LAD or LCX&#xD;
&#xD;
               4. Located within an arterial or saphenous vein graft or distal to a diseased&#xD;
                  arterial or saphenous vein graft&#xD;
&#xD;
               5. Lesion involving a side branch &gt;2mm in diameter or bifurcation&#xD;
&#xD;
               6. Previous placement of a scaffold proximal to or within 10 mm of the target lesion&#xD;
&#xD;
               7. Total occlusion (TIMI flow 0), or TIMI flow &lt; 1&#xD;
&#xD;
               8. Excessive tortuosity proximal to or within the lesion&#xD;
&#xD;
               9. Angulation (≥ 45o) proximal to or within the lesion&#xD;
&#xD;
              10. Calcification moderate or heavy&#xD;
&#xD;
              11. Previous intervention restenosis&#xD;
&#xD;
          -  The target vessel contains visible thrombus&#xD;
&#xD;
          -  Another clinically significant lesion (&gt;40%) is located in the same major epicardial&#xD;
             vessel as the target lesion&#xD;
&#xD;
          -  Patient has a high probability that a procedure other than pre-dilatation and&#xD;
             scaffolding and (if necessary) post-dilatation will be required at the time of index&#xD;
             procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or&#xD;
             brachytherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Abizaid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Verheye, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Middelheim Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ormiston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Schofer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz- und Gefäßzentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Middelheim Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. - Jan Ziekenhuis Z.O.L.</name>
      <address>
        <city>Genk</city>
        <zip>B-3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>Sao Paulo</city>
        <zip>0401210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICT / Instituto Do Coracao Do Triangulo Mineiro</name>
      <address>
        <city>Uberlandia</city>
        <zip>38400-368</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography Unit</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko-Amerykańskie Kliniki Serca</name>
      <address>
        <city>Dąbrowa Górnicza</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Interwencyjnego Leczenia Chorób Serca</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

